Business
Helix BioPharma Corp. Announces Upcoming Poster Presentation at the 20th European Molecular Imaging Meeting in Bilbao, Spain
(TheNewswire) March 11, 2025 – TheNewswire - Toronto, Ontario – Helix Bio...
About this update from Helix Biopharma Corp.
[{"type":"text","content":"Helix BioPharma Corp. Announces Upcoming Poster Presentation at the 20th European Molecular Imaging Meeting in Bilbao, Spain\n\n\n (TheNewswire)\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n March 11, 2025 – TheNewswire -\n \n\n Toronto, Ontario – Helix BioPharma Corp. (TSX:\n \n\n “HBP”\n \n\n , OTC PINK:\n \n\n “HBPCD”\n \n\n , FRANKFURT:\n \n\n “HBP0”\n \n\n ) (\n \n\n “Helix”\n \n\n or the\n \n\n “Company”\n \n\n ), a clinical-stage oncology company shaping a near future\nwhere today’s hard-to-treat cancers are vincible, is pleased to\nannounce an upcoming poster presentation highlighting the effects of\nTumour Defence Breaker™, L-DOS47, in CEACAM6-expressing head and\nneck cancer cells and colon adenocarcinoma cells in tumor-bearing mice\nat the 20\n \n\n th\n \n\n European Molecular Imaging Meeting (\n \n\n “EMIM 2025”\n \n\n )\ntaking place 11–14 March in Bilbao, Spain.\n \n\n\n\n The study demonstrated that L-DOS47 effectively\nneutralizes the acidic tumor microenvironment (TME) in new\nCEACAM6-expressing solid tumors, a critical factor in tumor\nprogression and immune evasion. In head and neck cancer and colon\nadenocarcinoma models, treatment with L-DOS47 raised tumor pH levels\nwithin 24 hours with a transient but measurable effect lasting up to\n48 hours, effectively neutralizing acidity that fuels tumor growth.\nMRI scans and tissue analysis also revealed signs of tumor necrosis,\nunderscoring L-DOS47’s impact on tumor viability. Importantly, the\nstudy confirmed that L-DOS47 precisely targets CEACAM6-expressing\ntumors while being safely cleared from the body. These results add to\nthe growing evidence that L-DOS47 is a powerful Tumour Defence\nBreaker™, shifting the tumor microenvironment to make prevalent,\nhard-to-treat cancers more vulnerable to treatment. The abstract and\nposter are publicly available on EMIM 2025’s Event Class via the\nfollowing link:\n \n\n\n\n https://www.eventclass.it/emim2025/scientific/online-program/poster-session?s=PO+01\n \n\n\n\n\n\n Poster details:\n \n\n\n\n Title:\n \n\n Paradigm Change in Oncoimmunology: Tumor antigen specific\nnormalization of the extracellular pH in the tumor microenvironment of\nsolid tumors by L-DOS47.\n \n\n\n\n Session:\n \n\n Po...